TNGX 8-K SEC Filing Analysis

Latest settled — T+20d

TNGX ▼ -12.16% at T+20d

NEUTRAL call ✗ call lost -12.16% · α vs SPY -12.19% · entry $23.02 → $20.22

Next anchor: T+60d in 8w

Currently $31.56 · +37.10% from $23.02 entry

Entry anchored
May 7, 03:59 PM ET
via Databento tick

T+1d

+2.00%

call +2.00% · α +1.77%

$23.48

settled 4w ago

T+5d

+8.04%

call +8.04% · α +6.57%

$24.87

settled 26d ago

T+20d

-12.16%

call -12.16% · α -12.19%

$20.22

settled yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Tango Therapeutics formalized the separation of former CFO Daniella Beckman, who was terminated without cause effective May 1, 2026. The separation agreement provides 12 months of base salary severance, COBRA premium reimbursement for up to 12 months, accelerated vesting of equity that would have vested over the next 24 months, and an extended stock option exercise period through August 31, 2026. This is a routine administrative filing formalizing a previously announced CFO departure with standard severance terms — no new material financial information or strategic implications.

Actionable Insight

No trading action warranted. The CFO departure was pre-announced and the separation terms are standard. Monitor for appointment of a permanent CFO and next quarterly earnings for any strategic updates.

Key Facts

CFO Daniella Beckman's employment terminated without cause effective May 1, 2026; separation agreement signed May 7, 2026
Severance includes 12 months of base salary paid in installments and COBRA premium reimbursement for up to 12 months
Equity acceleration: unvested time-based options and RSUs that would have vested over 24 months post-termination will accelerate and vest as of termination date
Stock option exercise period extended through August 31, 2026 for vested options
CFO departure was previously announced on April 10, 2026, effective April 15, 2026

Financial Impact

Severance of 12 months base salary (amount not disclosed) plus COBRA premiums for up to 12 months and accelerated equity vesting — immaterial relative to $3.4B market cap

cashshare count

Risk Factors

Prolonged CFO vacancy could create operational distraction
No permanent CFO replacement named — succession timeline unclear

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (18 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-213491
Document: d102174d8k.htm	0001193125-26-213491
Document: 0001193125-26-213491-index-headers.html	0001193125-26-213491
Document: 0001193125-26-213491-index.html	0001193125-26-213491
Document: 0001193125-26-213491.txt	0001193125-26-213491

8 reports for TNGX

T+1T+5T+20T+60

Filters

Reports for TNGX — sortable, filterable
	Type				Now
Jun 8, 2026 1d ago	424B5 BEARISH ★ 7/10	$30.93 awaiting T+20	awaiting T+20	—	$31.56 (−2.05%)
Jun 8, 2026 1d ago	8-K BULLISH ★ 7/10	$32.00 awaiting T+20	awaiting T+20	—	$31.56 (−1.38%)
May 8, 2026 4w ago	8-K NEUTRAL ★ 2/10	$23.02 $20.22	▼ −12.16%	▼ −12.19%	$31.56 (+37.10%)
Apr 24, 2026 6w ago	3 NEUTRAL ★ 2/10	$26.33 $20.04	▼ −23.89%	▼ −28.85%	$31.56 (+19.86%)
Apr 17, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$26.64 $24.87	▼ −6.64%	▼ −12.01%	$31.56 (+18.47%)
Apr 15, 2026 7w ago	8-K NEUTRAL ★ 3/10	$25.33 $23.50	▼ −7.22%	▼ −13.27%	$31.56 (+24.60%)
Mar 5, 2026 13w ago	8-K MIXED ★ 6/10	$16.83 $21.63	▲ +28.52%	▲ +32.31%	$31.56 (+87.52%)
Mar 5, 2026 13w ago	Press Release MIXED ★ 6/10	$16.83 $21.63	▲ +28.52%	▲ +32.31%	$31.56 (+87.52%)

US Market Status

Market Closed — Opens Thu (11h 12m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access